CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

← TherapeuticsMD, Inc. (TXMD) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫

TherapeuticsMD, Inc. (TXMD)

Pharmaceutical Preparations · market cap $25M · as of 2026-07-22

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst
2026-11-30 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
8
next 90d+
Dossier
Ready
cached
TherapeuticsMD (TXMD) is a micro-cap pharmaceutical company with a $24M market cap, 1 reported employee, and $8.4M in cash. The company's pipeline listing is unusually broad and eclectic — spanning dozens of assets across unrelated therapeutic areas — suggesting the disclosed pipeline reflects a data aggregation artifact or licensing/tracking portfolio rather than a wholly-owned internal pipeline. Revenue has collapsed from ~$87M in 2021 to ~$3M in 2025, and the company carries a net cash position of $8.4M against ongoing operating losses.
The catalyst path
  • 2026-11-30 (est.)Phase 2 · RNK08954imp 7/10
  • 2026-11-30 (est.)Phase 3 · GS1191-0445 injectionimp 9/10
  • 2026-12-15 (est.)Phase 2 · TH9619imp 7/10
  • 2027-02-15 (est.)Phase 2 · YL201 for Injectionimp 7/10
  • 2027-05-01 (est.)Phase 2 · ALT-100 mAbimp 7/10
  • 2027-05-15 (est.)Phase 3 · Leriglitazoneimp 9/10
  • 2027-06-15 (est.)Phase 3 · Veverimerimp 9/10
  • 2027-06-20 (est.)Phase 2 · CT3001imp 7/10
Pipeline
AssetPhaseIndication
KarXTPhase 3Psychosis Associated With Alzheimer's Disease
ATI-450Phase 2Hidradenitis Suppurativa
PTG-300Phase 2Polycythemia Vera
188-0551 SprayPhase 3Plaque Psoriasis
enclomiphene citratePhase 3Effect of Treatment on Bone Mineral Density
REL-1017Phase 3Major Depressive Disorder
DexycuPhase 3Inflammation
TDM-105795Phase 2Alopecia, Androgenetic
ETC-1002Phase 3Hypercholesterolemia
MSDC-0602KPhase 2Non-alcoholic Fatty Liver Disease
Human plateletsPhase 3Cardiac Surgery
PegtibatinasePhase 3Homocystinuria
Allo-QuadCAR01-TPhase 2Lymphoma Diffuse Large B-cell
188-0551 SolutionPhase 2Plaque Psoriasis
IG3018Phase 2Hyperuricemia
YL201 for InjectionPhase 2Advanced Solid Tumor
SerlopitantPhase 2Pruritus
intranasal carbetocinPhase 3Prader-Willi Syndrome
Halobetasol Propionate LotionPhase 2Psoriasis
XIAFLEX/XIAPEXPhase 3Dupuytren's Contracture
Price & technical context
3-month
-6.5%
6-month
-6.9%
12-month
+16.0%
52-wk range
$1.46–$2.77
vs 50-day MA
-4.2%
vs 200-day MA
-9.7%
Realized vol
66.2%
Max drawdown
-54.1%

Daily closes through 2026-11-16. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

Sources & data
  • SEC filings — EDGAR filings for TXMD (10-K, 10-Q, S-3, 13D/G, Form 4)
  • Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
  • Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
  • Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.